Results 11 to 20 of about 29,467 (290)
Direct-acting antivirals and visceral leishmaniasis: a case report [PDF]
BMC Infectious Diseases, 2019 Background Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions ...
Claudia Colomba +7 more
doaj +7 more sources
Current and Future Direct-Acting Antivirals Against COVID-19 [PDF]
Frontiers in Microbiology, 2020 The coronavirus disease of 2019 (COVID-19) has caused an unprecedented global crisis. The etiological agent is a new virus called the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As of October, 2020 there have been 45.4 million confirmed
Shiu-Wan Chan
doaj +3 more sources
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications [PDF]
Clinical Pharmacokinetics, 2016 Treatment options for chronic hepatitis C virus (HCV) infection have drastically changed since the development and licensing of new potent direct-acting antivirals (DAAs). The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes.
Smolders, E.J. +5 more
openaire +8 more sources
Management of Direct‐Acting Antiviral Failures [PDF]
Clinical Liver Disease, 2020 Answer questions and earn CME.
Maryam, Alimirah +2 more
openaire +2 more sources
Virus infection and direct-acting antivirals in pregnancy
Clinical and Experimental Obstetrics & Gynecology, 2022 Objective: Antiviral therapy during pregnancy has always presented difficulties in clinical practice. This review covers the safety and efficacy of the direct use of antivirals during pregnancy.
Xuan Huang, Jing Tang
doaj +1 more source
Treatment of Chronic HCV Infection with Direct Acting Antivirals
Central Asian Journal of Medical Sciences, 2021 Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs).
Bekhbold Dashtseren +12 more
doaj +1 more source
Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C
Регуляторные исследования и экспертиза лекарственных средств, 2023 Scientific relevance. Direct-acting antivirals have significantly improved the effectiveness of treatment for hepatitis C. However, Russia and the Eurasian Economic Union lack recommendations for the clinical development of medicinal products from this ...
A. I. Gubenko +3 more
doaj +1 more source
The Egyptian Journal of Internal Medicine, 2022 Background Direct-acting antivirals (DAAs) have revolutionized the therapy of HCV infection with higher sustained virological response (SVR) rates. Fibrosis regression after achieving SVR to DAA remains to be evaluated in chronic hepatitis C patients ...
Ramy H. Agwa +5 more
doaj +1 more source
Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study [PDF]
Clinical and Molecular Hepatology, 2017 Background/Aims Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons.
Kwang Il Seo +5 more
doaj +1 more source
Acta Scientiarum. Health Sciences, 2023 To report the sociodemographic and clinical profile of patients treated with direct-action antivirals (DAAs). Patients infected with hepatitis C virus in current treatment were followed up in a pharmaceutical office.
Karem Aline Pegoraro +3 more
doaj +1 more source